<DOC>
	<DOCNO>NCT00057499</DOCNO>
	<brief_summary>Insulin dependent diabetes mellitus ( also call type 1 diabetes mellitus T1DM ) cause destruction insulin-producing cell pancreas . People T1DM produce enough insulin , necessary proper regulation blood sugar level . T1DM autoimmune disease . An autoimmune disease disease body 's immune system attack body . In addition regulating blood sugar , insulin may ability protect cell pancreas attack immune system . This study evaluate whether insulin-based vaccine protect cell autoimmune destruction . Study hypothesis : IFA-enhanced human insulin B-chain vaccination lead arrest slow ongoing autoimmunity , result appreciable difference functioning B cell mass compare placebo treat group end study .</brief_summary>
	<brief_title>Evaluation Diabetes Vaccine Newly Diagnosed Diabetics</brief_title>
	<detailed_description>The vaccine study , IBC-VSO1 , synthetic , metabolically inactive form insulin design prevent pancreatic beta-cell destruction . It cause fluctuation blood sugar . This study evaluate whether vaccine protects autoimmune attack onset T1DM , pancreas function deteriorate . This experimental treatment must occur early 60 % 85 % beta-cells already destroyed time T1DM diagnosis . If beta-cell destruction halt , prolonged remission period diagnosis may occur , subsequent delay diabetes-related complication . Participants must diagnose T1DM 3 month time enrollment study . Participants randomly assign either vaccine group control group . Participants vaccine group receive one injection IBC-VS01 ; participant control group receive placebo . Participants monitor 2 year . Participants ten follow-up visit , include blood test immunological genetic analysis . Throughout study , metabolic test also perform measure remain capacity self insulin production body .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Diagnosed type 1 diabetes mellitus within 3 month prior study entry Positive IAA , GAD65 , IA2 antibodies OR positive GAD65 IA2 antibodies 2 week start insulin treatment History treatment oral hypoglycemic agent 3 month Ongoing use medication know influence glucose tolerance History immunosuppressive steroid therapy 3 month within 2 year prior study entry Severe active liver , heart , kidney , immunodeficiency disease may limit life expectancy may require immunosuppression study Prior complication related routine vaccination Prior participation trial prevention type 1 diabetes mellitus . Individuals know placebo arm complete prevention trial exclude . Any condition may interfere participant 's ability comply study Pregnancy plan pregnancy within time frame study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Juvenile diabetes</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Insulin</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Type 1 Diabetes</keyword>
	<keyword>Diabetes Mellitus</keyword>
</DOC>